Individuals Discontinuing Slimming Medications Regain Pounds at a Quadrupled Rate Compared to People Using Diet and Exercise

A recent study reveals that people who stop using blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight much more quickly than those who stop conventional lifestyle programs.

Research printed in a major health publication demonstrates that while obese people can lose a large proportion of their total mass while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month after stopping.

"Individuals using such medications need to be aware of the potential of rapid rebound weight gain when the treatment is stopped," stated researcher Dr. Susan Jebb.

This pace of recovery implies a return to starting mass within about a year and a half.

Analyzing Treatments

The study, which looked at 37 of studies involving over 9,000 of participants, compared the outcomes of the injectable medications with older methods.

Researchers note that individuals who shed pounds through diet and exercise generally experience a more gradual weight regain—perhaps 0.1 kg a month—post-intervention.

Explaining the Fast Rebound

Experts believe the way of the injections is key to understanding the amplified rebound.

These medications imitate a natural hormone called GLP-1, which helps regulate feelings of fullness.

"Sustained high doses of GLP-1 concentrations far above than the body's typical production may cause the system to generate a reduced amount of its own natural GLP-1, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.

"Stopping of this GLP-1 'fix' means appetite is uncontrolled, making binge eating far more likely."

An Ongoing Issue?

Medical guidelines suggest the injections for people with weight-linked medical conditions, alongside recommended lifestyle changes.

Professionals say that, due to the significant potential of weight regain, the therapy might need to be life-long.

This view is supported by pharmaceutical companies, who state that the findings "underscore the chronic character of obesity," similar to managing diseases like hypertension.

Patient Experiences

People who have stopped the jabs report a sudden return of cravings.

"It was like a trigger flipping and you become starving," recalled a patient.

The struggle is compounded if users have not adopted sustainable lifestyle or habit changes during treatment.

Significant Adoption

Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with demand being substantial.

• Use is higher among women compared to men.
• The 40s and 50s age group shows the highest level of interest.
• Many access the drugs through private prescriptions rather than public health services.

In conclusion, clinicians caution that while the jabs are powerful tools for shedding pounds, they are not a permanent solution and lasting health benefits likely depends on integrated behavioural management.